Visanne Study to Assess Safety in Adolescents
Launched by BAYER · Jan 25, 2011
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female adolescents after menarche (12 - less than 18 years of age) at screening. For Finland: Adolescents aged 12 - 14 years old who present with clinical features of endometriosis will only be enrolled into the study if their diagnosis of endometriosis has been confirmed by laparoscopy.
- * Dysmenorrhea of at least moderate intensity, with or without chronic pelvic pain, for at least 2 cycles in the previous 4 months and one of the following conditions:
- • Clinically suspected endometriosis based on the presence of pelvic pain incompletely relieved by non steroidal anti-inflammatory drugs and/or oral contraceptives
- • Any abdominal pain associated with ultrasound findings suggestive of endometriosis (abdominal, vaginal or rectal; only after additional specific consent and assent)
- • Failure of surgical treatment for endometriosis (with cyclic or chronic pelvic pain of at least 4 months duration postsurgery)
- • Threshold for endometriosis-associated pelvic pain (EAPP) score: at least 30 on a 100 units visual analog scale retrospectively evaluated at screening for the last 4 weeks
- Exclusion Criteria:
- • Absence of endometriosis at laparoscopy
- • Previous application of hormonal agents including oral contraceptives within 2 months, progestins, danazol within 3 months, and Gonadotropin Releasing Hormone (GnRH) agonists within 6 months prior to start of treatment
- • Chronic pelvic pain that might be related to genitourinary disease or to chronic or recurrent gastrointestinal disease, including irritable bowel syndrome (defined as a disease characterized by pain relieved by defecation and irregular defecation patterns lasting at least 3 months)
- • Clinically established need for primary surgical treatment of endometriosis
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Innsbruck, , Austria
Valencia, , Spain
Berlin, , Germany
Hamburg, , Germany
Wien, , Austria
Münster, Nordrhein Westfalen, Germany
Linz, Oberösterreich, Austria
Erlangen, Bayern, Germany
Paris, , France
Rouen, , France
Sevilla, , Spain
St. Pölten, Niederösterreich, Austria
Le Kremlin Bicetre, , France
Vigo, , Spain
Helsinki, , Finland
Turku, , Finland
Espoo, , Finland
Praha 2, , Czech Republic
Lübeck, Schleswig Holstein, Germany
Brno, , Czech Republic
Oldenburg, Niedersachsen, Germany
Angers Cedex 01, , France
Westerstede, , Germany
Benidorm, Alicante, Spain
Ceske Budejovice, , Czech Republic
Pisek, , Czech Republic
Praha, , Czech Republic
Graz, Steiermark, Austria
Patients applied
Trial Officials
Bayer Study Director
Study Director
Bayer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials